Cargando…

Isotretinoin and adverse neuropsychiatric outcomes: retrospective cohort study using routine data

BACKGROUND: Severe neuropsychiatric outcomes have been reported in individuals exposed to isotretinoin, but the evidence is inconclusive and complicated by several methodological limitations. OBJECTIVES: To establish and quantify the association between isotretinoin use for acne and 1‐year incident...

Descripción completa

Detalles Bibliográficos
Autores principales: Paljarvi, Tapio, McPherson, Tess, Luciano, Sierra, Herttua, Kimmo, Fazel, Seena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543533/
https://www.ncbi.nlm.nih.gov/pubmed/35174880
http://dx.doi.org/10.1111/bjd.21049
_version_ 1784804395524816896
author Paljarvi, Tapio
McPherson, Tess
Luciano, Sierra
Herttua, Kimmo
Fazel, Seena
author_facet Paljarvi, Tapio
McPherson, Tess
Luciano, Sierra
Herttua, Kimmo
Fazel, Seena
author_sort Paljarvi, Tapio
collection PubMed
description BACKGROUND: Severe neuropsychiatric outcomes have been reported in individuals exposed to isotretinoin, but the evidence is inconclusive and complicated by several methodological limitations. OBJECTIVES: To establish and quantify the association between isotretinoin use for acne and 1‐year incident neuropsychiatric adverse outcomes. METHODS: A propensity score‐matched cohort study of electronic medical records between the years 2013 and 2019 with patients followed up for 1 year after their index dispensed prescription was conducted. The database included over 12 million patients aged 12–27 years. We analysed data for individuals with acne in this age range with a dispensed prescription for isotretinoin or a control prescription. Outcomes included diagnoses of any incident sleep or mental health disorder, or nonfatal self‐harm within 1 year of the index prescription. RESULTS: We included 30 866 patients prescribed isotretinoin for their acne, 44 748 prescribed oral antibiotics, 108 367 prescribed topical anti‐acne agents and 78 666 patients with acne but without an anti‐acne prescription. After propensity score matching for baseline confounders, the odds ratio (OR) for any incident neuropsychiatric outcomes in patients with acne exposed to isotretinoin was 0·80 [95% confidence interval (CI) 0·74–0·87] compared with those on oral antibiotics; 0·94 (95% CI 0·87–1·02) compared with those using topical anti‐acne medicines; and 1·06 (95% CI 0·97–1·16) compared with those without a prescription for anti‐acne medicines. Patients exposed to isotretinoin experienced significantly more incident physical symptoms than patients in any of the three comparison cohorts. CONCLUSIONS: Isotretinoin was not independently associated with excess adverse neuropsychiatric outcomes at the population level. When monitoring potential adverse outcomes during isotretinoin treatment, clinicians should also consider the high mental health burden associated with treatment‐resistant acne and the potential contribution of physical side‐effects of prescribed medication on mental health.
format Online
Article
Text
id pubmed-9543533
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-95435332022-10-14 Isotretinoin and adverse neuropsychiatric outcomes: retrospective cohort study using routine data Paljarvi, Tapio McPherson, Tess Luciano, Sierra Herttua, Kimmo Fazel, Seena Br J Dermatol Original Articles BACKGROUND: Severe neuropsychiatric outcomes have been reported in individuals exposed to isotretinoin, but the evidence is inconclusive and complicated by several methodological limitations. OBJECTIVES: To establish and quantify the association between isotretinoin use for acne and 1‐year incident neuropsychiatric adverse outcomes. METHODS: A propensity score‐matched cohort study of electronic medical records between the years 2013 and 2019 with patients followed up for 1 year after their index dispensed prescription was conducted. The database included over 12 million patients aged 12–27 years. We analysed data for individuals with acne in this age range with a dispensed prescription for isotretinoin or a control prescription. Outcomes included diagnoses of any incident sleep or mental health disorder, or nonfatal self‐harm within 1 year of the index prescription. RESULTS: We included 30 866 patients prescribed isotretinoin for their acne, 44 748 prescribed oral antibiotics, 108 367 prescribed topical anti‐acne agents and 78 666 patients with acne but without an anti‐acne prescription. After propensity score matching for baseline confounders, the odds ratio (OR) for any incident neuropsychiatric outcomes in patients with acne exposed to isotretinoin was 0·80 [95% confidence interval (CI) 0·74–0·87] compared with those on oral antibiotics; 0·94 (95% CI 0·87–1·02) compared with those using topical anti‐acne medicines; and 1·06 (95% CI 0·97–1·16) compared with those without a prescription for anti‐acne medicines. Patients exposed to isotretinoin experienced significantly more incident physical symptoms than patients in any of the three comparison cohorts. CONCLUSIONS: Isotretinoin was not independently associated with excess adverse neuropsychiatric outcomes at the population level. When monitoring potential adverse outcomes during isotretinoin treatment, clinicians should also consider the high mental health burden associated with treatment‐resistant acne and the potential contribution of physical side‐effects of prescribed medication on mental health. John Wiley and Sons Inc. 2022-04-12 2022-07 /pmc/articles/PMC9543533/ /pubmed/35174880 http://dx.doi.org/10.1111/bjd.21049 Text en © 2022 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Paljarvi, Tapio
McPherson, Tess
Luciano, Sierra
Herttua, Kimmo
Fazel, Seena
Isotretinoin and adverse neuropsychiatric outcomes: retrospective cohort study using routine data
title Isotretinoin and adverse neuropsychiatric outcomes: retrospective cohort study using routine data
title_full Isotretinoin and adverse neuropsychiatric outcomes: retrospective cohort study using routine data
title_fullStr Isotretinoin and adverse neuropsychiatric outcomes: retrospective cohort study using routine data
title_full_unstemmed Isotretinoin and adverse neuropsychiatric outcomes: retrospective cohort study using routine data
title_short Isotretinoin and adverse neuropsychiatric outcomes: retrospective cohort study using routine data
title_sort isotretinoin and adverse neuropsychiatric outcomes: retrospective cohort study using routine data
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543533/
https://www.ncbi.nlm.nih.gov/pubmed/35174880
http://dx.doi.org/10.1111/bjd.21049
work_keys_str_mv AT paljarvitapio isotretinoinandadverseneuropsychiatricoutcomesretrospectivecohortstudyusingroutinedata
AT mcphersontess isotretinoinandadverseneuropsychiatricoutcomesretrospectivecohortstudyusingroutinedata
AT lucianosierra isotretinoinandadverseneuropsychiatricoutcomesretrospectivecohortstudyusingroutinedata
AT herttuakimmo isotretinoinandadverseneuropsychiatricoutcomesretrospectivecohortstudyusingroutinedata
AT fazelseena isotretinoinandadverseneuropsychiatricoutcomesretrospectivecohortstudyusingroutinedata